MedTrace Logo

Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery

NCT02984111 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2017-10-24

No results posted yet for this study

Summary

The aim of this trail is to assess the safety and therapeutic effects of single EPO intervention in different times during coronary surgery in changes of inflammatory response.

Conditions

  • Myocardial Ischemic Reperfusion Injury

Interventions

DRUG

normal saline

DRUG

erythropoietin

Sponsors & Collaborators

  • Pooyesh Darou

    collaborator OTHER

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Mahnoosh Foroughi, MD, · Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences. Tehran, Iran.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-01-31
Completion
2017-06-30

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02984111 on ClinicalTrials.gov